COLO.B.DK

694.2

-0.46%↓

GMAB.DK

1,283.5

+0.04%↑

ZEAL.DK

458

+0.44%↑

HLUNB.DK

31.9

+0.63%↑

AMBUB.DK

114.6

+0.35%↑

COLO.B.DK

694.2

-0.46%↓

GMAB.DK

1,283.5

+0.04%↑

ZEAL.DK

458

+0.44%↑

HLUNB.DK

31.9

+0.63%↑

AMBUB.DK

114.6

+0.35%↑

COLO.B.DK

694.2

-0.46%↓

GMAB.DK

1,283.5

+0.04%↑

ZEAL.DK

458

+0.44%↑

HLUNB.DK

31.9

+0.63%↑

AMBUB.DK

114.6

+0.35%↑

COLO.B.DK

694.2

-0.46%↓

GMAB.DK

1,283.5

+0.04%↑

ZEAL.DK

458

+0.44%↑

HLUNB.DK

31.9

+0.63%↑

AMBUB.DK

114.6

+0.35%↑

COLO.B.DK

694.2

-0.46%↓

GMAB.DK

1,283.5

+0.04%↑

ZEAL.DK

458

+0.44%↑

HLUNB.DK

31.9

+0.63%↑

AMBUB.DK

114.6

+0.35%↑

Search

Novo Nordisk A-S (Class B)

Отворен

463.2 -0.8

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

455.2

Максимум

471.05

Ключови измерители

By Trading Economics

Приходи

929M

28B

Продажби

14B

86B

P/E

Средно за сектора

20.778

63.778

EPS

6.34

Дивидентна доходност

3.33

Марж на печалбата

32.947

Служители

76,302

EBITDA

4.1B

39B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+9.53% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

3.33%

2.39%

Следващи печалби

7.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-31B

2.1T

Предишно отваряне

464

Предишно затваряне

463.2

Novo Nordisk A-S (Class B) Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

25.02.2025 г., 15:33 ч. UTC

Значими двигатели на пазара

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

5.02.2025 г., 11:53 ч. UTC

Печалби

Novo Nordisk Outlook Provides Some Welcome Relief -- 2nd Update

5.02.2025 г., 08:19 ч. UTC

Печалби

Novo Nordisk Expects Slowing Sales Growth This Year -- Update

2.04.2025 г., 11:25 ч. UTC

Пазарно говорене

Novo Nordisk Is a Screaming Buy, AlphaValue Says -- Market Talk

2.04.2025 г., 09:27 ч. UTC

Горещи акции

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

31.03.2025 г., 12:49 ч. UTC

Пазарно говорене

Novo Nordisk Had Constructive Quarter, But U.S. Volumes a Concern -- Market Talk

28.03.2025 г., 15:11 ч. UTC

Пазарно говорене

Novo Nordisk First Quarter Earnings Could Disappoint, BofA Says -- Market Talk

27.03.2025 г., 13:45 ч. UTC

Пазарно говорене
Печалби

Novo Nordisk's Wegovy Sales Growth Stalls in U.S. Amid Competition, Reimbursement Hurdles -- Market Talk

24.03.2025 г., 10:19 ч. UTC

Пазарно говорене

Novo Nordisk's Ozempic Drug Faces Declining Sales -- Market Talk

24.03.2025 г., 09:08 ч. UTC

Пазарно говорене
Печалби

Novo Nordisk Shares Could Remain Under Pressure for Now -- Market Talk

19.03.2025 г., 15:54 ч. UTC

Топ новини

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

11.03.2025 г., 15:31 ч. UTC

Пазарно говорене

Novo Nordisk's CagriSema Trial Shows Disappointing Weight Loss -- Market Talk

11.03.2025 г., 14:58 ч. UTC

Пазарно говорене

Novo Nordisk's CagriSema Results Fail to Impress -- Market Talk

28.02.2025 г., 12:00 ч. UTC

Топ новини

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

10.02.2025 г., 12:00 ч. UTC

Топ новини

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

7.02.2025 г., 10:30 ч. UTC

Топ новини

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6.02.2025 г., 16:16 ч. UTC

Топ новини
Печалби

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

6.02.2025 г., 14:56 ч. UTC

Печалби

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

5.02.2025 г., 13:59 ч. UTC

Печалби

Novo Nordisk Outlook Provides Some Welcome Relief -- WSJ

5.02.2025 г., 12:02 ч. UTC

Печалби

Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns. -- Barrons.com

5.02.2025 г., 11:35 ч. UTC

Пазарно говорене
Печалби

Novo Nordisk's Earnings Report Should Get It Back On Track -- Market Talk

5.02.2025 г., 10:10 ч. UTC

Горещи акции

Stocks to Watch Wednesday: AMD, Alphabet, Novo Nordisk -- WSJ

5.02.2025 г., 09:43 ч. UTC

Печалби

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

5.02.2025 г., 08:47 ч. UTC

Пазарно говорене
Печалби

Novo Nordisk's Robust Sales Outlook is Reassuring -- Market Talk

5.02.2025 г., 08:38 ч. UTC

Пазарно говорене
Печалби

Novo Nordisk Earnings, Guidance Imply Consensus Upgrades -- Market Talk

5.02.2025 г., 08:32 ч. UTC

Печалби

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

5.02.2025 г., 08:30 ч. UTC

Пазарно говорене
Печалби

Novo Nordisk Sales Guidance Materially Ahead of Expectations -- Market Talk

5.02.2025 г., 06:46 ч. UTC

Печалби

Novo Nordisk Expects to File For First Regulatory Approval of CagriSema During 1Q26

5.02.2025 г., 06:45 ч. UTC

Печалби

Novo Nordisk Plans to Initiate New CagriSema Phase 3 Trial in 2025 to Further Explore Weight Loss Potential

5.02.2025 г., 06:43 ч. UTC

Печалби

Novo Nordisk: 2025 Free Cash Flow Expected to be DKK75B-DKK85B

Сравнение с други в отрасъла

Ценова промяна

Novo Nordisk A-S (Class B) Прогноза

Ценова цел

By TipRanks

9.53% нагоре

12-месечна прогноза

Среден 1,162.73 DKK  9.53%

Висок 1,550 DKK

Нисък 720 DKK

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Novo Nordisk A-S (Class B) през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

11 ratings

7

Купи

2

Задържане

2

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.